Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors.

Saved in:
Bibliographic Details
Title: Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors.
Authors: Nataraj NB; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel., Noronha A; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel., Lee JS; Cancer Data Science Lab, National Cancer Institute, NIH, Rockville, MD, USA., Ghosh S; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel., Mohan Raju HR; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel., Sekar A; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel., Zuckerman B; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel., Lindzen M; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel., Tarcitano E; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel., Srivastava S; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel., Selitrennik M; Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Livneh I; Technion Integrated Cancer Center (TICC) and the Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa, Israel., Drago-Garcia D; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel., Rueda O; Cancer Research UK Cambridge Institute, University of Cambridge and the Cambridge Cancer Centre, Department of Oncology, Cambridge, UK., Caldas C; Cancer Research UK Cambridge Institute, University of Cambridge and the Cambridge Cancer Centre, Department of Oncology, Cambridge, UK., Lev S; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel., Geiger T; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel; Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Ciechanover A; Technion Integrated Cancer Center (TICC) and the Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa, Israel., Ulitsky I; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel., Seger R; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel., Ruppin E; Cancer Data Science Lab, National Cancer Institute, NIH, Rockville, MD, USA., Yarden Y; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel. Electronic address: yosef.yarden@weizmann.ac.il.
Source: Cell reports [Cell Rep] 2022 Feb 22; Vol. 38 (8), pp. 110418.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101573691 Publication Model: Print Cited Medium: Internet ISSN: 2211-1247 (Electronic) NLM ISO Abbreviation: Cell Rep Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2211-1247
DOI:10.1016/j.celrep.2022.110418